Depletion of high-content CD14+ cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing

Depletion of high-content CD14+ cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing

With the US Food and Drug Administration (FDA) approval of four CD19- and one BCMA-targeted chimeric antigen receptor (CAR) therapy for B cell malignancies, CAR T cell therapy has finally reached the status of a medicinal product. The successful manufacturing of autologous CAR T cell products is a k...

Full description

Bibliographic Details
Main Authors: Xiuyan Wang, Oriana Borquez-Ojeda, Jolanta Stefanski, Fang Du, Jinrong Qu, Jagrutiben Chaudhari, Keyur Thummar, Mingzhu Zhu, Ling-bo Shen, Melanie Hall, Paridhi Gautam, Yongzeng Wang, Brigitte Sénéchal, Devanjan Sikder, Prasad S. Adusumilli, Renier J. Brentjens, Kevin Curran, Mark B. Geyer, Sham Mailankhody, Roisin O’Cearbhaill, Jae H. Park, Craig Sauter, Susan Slovin, Eric L. Smith, Isabelle Rivière
Format: Article
Language:English
Published: Elsevier 2021-09-01
Series:Molecular Therapy: Methods & Clinical Development
Subjects:
CAR T cell
cGMP
clinical grade
large-scale manufacturing
monocyte depletion
Online Access:http://www.sciencedirect.com/science/article/pii/S2329050121001169

Internet

http://www.sciencedirect.com/science/article/pii/S2329050121001169

Similar Items